Similar articles for PMID: 24970869

Year	Number of Results
1970	1
1974	1
1978	1
1988	2
1989	1
1990	1
1991	3
1992	3
1994	2
1995	2
1996	4
1998	5
1999	7
2000	4
2001	8
2002	7
2003	11
2004	6
2005	9
2006	13
2007	16
2008	13
2009	11
2010	9
2011	15
2012	17
2013	17
2014	20
2015	12
2016	21
2017	24
2018	16
2019	8
2020	13
2021	1

1

A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.

Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM. Coyne DW, et al. Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1620-6. doi: 10.2215/CJN.10661013. Epub 2014 Jun 26. Clin J Am Soc Nephrol. 2014. PMID: 24970869 Free PMC article. Clinical Trial.

2

Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.

Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Sprague SM, et al. Kidney Int. 2003 Apr;63(4):1483-90. doi: 10.1046/j.1523-1755.2003.00878.x. Kidney Int. 2003. PMID: 12631365 Free article. Clinical Trial.

3

Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.

Capuano A, Serio V, Pota A, Memoli B, Andreucci VE. Capuano A, et al. J Nephrol. 2009 Jan-Feb;22(1):59-68. J Nephrol. 2009. PMID: 19229819

4

Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.

Borrego Utiel FJ, Bravo Soto JA, Merino Pérez MJ, González Carmelo I, López Jiménez V, García Álvarez T, Acosta Martínez Y, Mazuecos Blanca MA. Borrego Utiel FJ, et al. Nefrologia. 2015;35(4):363-73. doi: 10.1016/j.nefro.2015.06.018. Epub 2015 Aug 4. Nefrologia. 2015. PMID: 26306956 Free article. English, Spanish.

5

Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.

Jamaluddin EJ, Gafor AH, Yean LC, Cader R, Mohd R, Kong NC, Shah SA. Jamaluddin EJ, et al. Clin Exp Nephrol. 2014 Jun;18(3):507-14. doi: 10.1007/s10157-013-0844-2. Epub 2013 Aug 2. Clin Exp Nephrol. 2014. PMID: 23903802 Clinical Trial.

6

Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.

Martin KJ, González EA, Gellens ME, Hamm LL, Abboud H, Lindberg J. Martin KJ, et al. Am J Kidney Dis. 1998 Oct;32(2 Suppl 2):S61-6. doi: 10.1053/ajkd.1998.v32.pm9808145. Am J Kidney Dis. 1998. PMID: 9808145 Clinical Trial.

7

19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.

Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J. Martin KJ, et al. J Am Soc Nephrol. 1998 Aug;9(8):1427-32. J Am Soc Nephrol. 1998. PMID: 9697664 Free article. Clinical Trial.

8

Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.

Llach F, Yudd M. Llach F, et al. Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S45-50. doi: 10.1053/ajkd.2001.28114. Am J Kidney Dis. 2001. PMID: 11689387

9

Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.

Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM. Ross EA, et al. Am J Nephrol. 2008;28(1):97-106. doi: 10.1159/000109398. Epub 2007 Oct 3. Am J Nephrol. 2008. PMID: 17914251 Clinical Trial.

10

Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.

Akizawa T, Akiba T, Hirakata H, Kinugasa E, Tominaga Y, Fukagawa M, Yokoyama K, Zhang W, Linde PG, Suzuki M. Akizawa T, et al. Ther Apher Dial. 2015 Jun;19(3):225-34. doi: 10.1111/1744-9987.12242. Epub 2014 Nov 3. Ther Apher Dial. 2015. PMID: 25363733 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed